Multiple Sclerosis (MS)
JVC Antibody program in patients with relapsing MS or considering treatment with Tysabri®. Requires blood sample collection at enrollment and annually thereafter for two years
To better understand whether antibodies to JCV may be used to predict whether a patient is at higher or lower risk for developing Progressive Multifocal Encephalopathy (PML)
Key Inclusion Criteria
Patients with relapsing MS receiving commercial Tysabri and patients being considered for such treatment.
Key Exclusion Criteria
Patients participating in any other Tysabri clinical trial or study sponsored by Biogen Idec or Elan may not participate in this study.